We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Risk Factors Associated with Lou Gehrig's Disease

By Biotechdaily staff writers
Posted on 17 Apr 2007
Thirty-four unique variations in the human genetic code were identified and may explain the underlying factors that contribute to amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. More...


Under the direction of John Hardy, Ph.D. and Bryan Traynor, M.D., from the U.S. National Institute on Aging's Laboratory of Neurogenetics (Bethesda, MD, USA) and the Section on Developmental Genetic Epidemiology, U.S. National Institute of Mental Health (Bethesda, MD, USA), Illumina's (San Diego, CA, USA) HumanHap550 BeadChip was used to produce more than 300 million genotypes in a search for those single nucleotide polymorphisms (SNPs) that increase risk for ALS. ALS fatally attacks 10,000 Americans each year with an estimated one in 1,000 people is at risk of developing the disease.

A key goal of our product development efforts is to provide backwards compatibility for our customers. This means that as we develop new generations of products, current customers have the seamless ability to achieve the same level of content as found on the new BeadChip, said Carsten Rosenow, DNA analysis marketing manager. For example the HumanHap240S and HumanHap450S BeadChips give researchers the opportunity to upgrade from the HumanHap300 and HumanHap550 respectively, obtaining the same level of content as found on the HumanHap550 and Human 1M.

We recognize the importance of developing technologies that are powerful and scalable, and that deliver industry-leading value that enable users to find the answers they need. The Lou Gehrig's disease studies are an example of how our tools are being used to accelerate the discovery of association markers for complex disease, said Jay Flatley, president and CEO of Illumina.

The HumanHap240S Genotyping BeadChip contains 240,000 tag SNPs derived from the phase I and II HapMap data, and provides tag SNP coverage in regions of lower linkage disequilibrium in the genome. The addition of the HumanHap240S to the HumanHap300, which contains 317,000 tagSNPs derived from the phase I HapMap data, provides the same level of comprehensive genomic coverage across multiple populations as found on the HumanHap550.

All three BeadChips are powered by the Infinium assay, which enables intelligent SNP selection utilizing tagSNPs. The HumanHap300 is now available in a two-sample BeadChip (HumanHap300-Duo) and can be customized with up to 60,800 additional custom Beadtypes (HumanHap300-Duo+). The HumanHap550 can also be customized with up to 121,600 additional Beadtypes (HumanHap500+).

The study was published in the journal Lancet Neurology on March 12, 2007.


Related Links:
Institute of Aging
National Institute of Mental Health
Illumina

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.